Episode
#200: Insulin and QWINT-1 Trial in T2DM: Beyond Journal Club Segment with NEJM Group
- Published
- Feb 11, 2026
- Duration seconds
- 1694
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/200-insulin-and-qwint-1-trial-in-t2dm-beyond-journal-club-segment-with-nejm-group/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/200-insulin-and-qwint-1-trial-in-t2dm-beyond-journal-club-segment-with-nejm-group.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
From metformin to basal insulin to overlooked older medications, this episode reviews the T2D medication toolkit clinicians use every day. We then dive into new evidence on once-weekly insulin to help you individualize therapy while reducing treatment burden. 🔹 Sponsor : Pain Management and Opioids Adaptive Learning Free Online Course by NEJM Group: https://cme-info.nejm.org/core-im/ 🔹 Transcript and Shownotes : 00.58 | Insulin Hx & Types 06:00 | Indications for Insulin and the Burden on Patients 08:26 | What is the QWINT-1 Trial? 16:18 | Discussion Tags: CoreIM, Internal Medicine, Evidence-Based Medicine, Insulin Resistance, Clinical Reasoning, Hospital Medicine, Medical Education, Endocrine, Endocrinology Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy